Recorlev (levoketoconazole) Prior Authorization Request Form Caterpillar Prescription Drug Benefit

Phone: 877-228-7909 Fax: 800-424-7640

Instructions: Please fill out all applicable sections completely and legibly. Attach any additional documentation that is important for the review (e.g., chart notes or lab data, to support the authorization request). Information contained in this form is Protected Health Information under HIPAA.

MEMBER INFORMATION				
LAST NAME:	FIRST NAME:			
PHONE NUMBER:	DATE OF BIRTH:			
STREET ADDRESS:	1			
CITY:	STATE: ZIP CODE:			
PATIENT INSURANCE ID NUMBER:				
MALE FEMALE HEIGHT (IN/CM): WEIGHT (LB/KG): ALLERGIES: IF YOU ARE NOT THE PATIENT OR THE PRESCRIBER, YOU WILL NEED TO SUBMIT A PHI DISCLOSURE AUTHORIZATION FORM WITH THIS REQUEST WHICH CAN BE FOUND AT THE FOLLOWING LINK: PRIMETHERAPEUTICS.COM/NOPP PATIENT'S AUTHORIZED REPRESENTATIVE (IF APPLICABLE):				
AUTHORIZED REPRESENTATIVE'S PHONE NUMBER:				
PRESCRIBER INFORMATION				
LAST NAME:	FIRST NAME:			
PRESCRIBER SPECIALTY:	EMAIL ADDRESS:			
NPI NUMBER:	DEA NUMBER:			
PHONE NUMBER:	FAX NUMBER:			
STREET ADDRESS:				

CITY:	STATE:	ZIP CODE:
REQUESTOR (if different than prescriber):	OFFICE CONTACT PERSON:	

MEDICATION OR MEDICAL DISPENSING INFORMATION					
MEDICATION NAME:					
DOSE/STRENGTH:	FREQUENCY:	LENGTH OF THERAPY/REFILLS:	QUANTITY:		
NEW THERAPY		IF RENEWAL: DATE THERAPY INITIATED:			
DURATION OF THERAPY (SPECIFIC DATES):					

Continued on next page.



URGENT

Recorlev (levoketoconazole) Prior Authorization Request Form

Caterpillar Prescription Drug Benefit Phone: 877-228-7909 Fax: 800-424-7640

MEMBER'S LAST NAME:	MEMBER'S FIRST NAME:		
1. HAS THE PATIENT TRIED ANY OTHER	R MEDICATIONS FOR THIS CONDITION?	YES (if yes, complete below) 📃 NO	
MEDICATION/THERAPY (SPECIFY DRUG NAME AND DOSAGE):	DURATION OF THERAPY (SPECIFY DATES):	RESPONSE/REASON FOR FAILURE/ALLERGY:	
2. LIST DIAGNOSES:		ICD-10:	
Hyperortisolemia secondary to endogen	ous Cushing's Syndrome		
Other diagnosis:	ICD-10:		
	: PLEASE PROVIDE ALL RELEVANT CLINIC	AL INFORMATION TO SUPPORT A	
Initial Request:			
Is the prescriber an endocrinologist?	Yes 🗆 No		
Does the patient have hypercortisolen	nia? 🗆 Yes 🗆 No		
Is the patient's hypercortisolemia due	to endogenous Cushing's Syndrome?	IYes 🗆 No	
 Please provide documentation. an ACTH-dependent (e.g., pituitary) an ACTH-independent (e.g., adrend Select if the patient has tried at least 2 Metyrapone Ketoconazole Has the patient failed surgery or are t 	e caused by one of the following? y corticotrope adenoma, ectopic secretic coortical adenoma, adrenocortical carci 2 of the listed therapies: <i>(*Please provi</i> hey not a candidate for surgery?* yeted by a surgeon or anesthesiologist co	on of ACTH by nonpituitary tumor), noma, nodular adrenal hyperplasia ide documentation.) s 🗆 No	
Renewal Request: Is the prescriber an endocrinologist? □			
Does the patient have a blood cortisol Yes No 	level or urinary free cortisol level at or documentation.	below the upper limit of normal?	
Was the lab blood cortisol level or urin renewal?	nary free cortisol level drawn more thar	1 30 days prior to the request for	
Are there any other comments, diagno physician feels is important to this rev	oses, symptoms, medications tried or fa iew?	iled, and/or any other information the	
Please note: Not all drugs/diagnosis are information is received.	e covered on all plans. This request may	be denied unless all required	



Recorlev (levoketoconazole) Prior Authorization Request Form

Caterpillar Prescription Drug Benefit Phone: 877-228-7909 Fax: 800-424-7640

MEMBER'S LAST NAME: ____

MEMBER'S FIRST NAME: ___

ATTESTATION: I attest the information provided is true and accurate to the best of my knowledge. I understand that the Health Plan, insurer, Medical Group or its designees may perform a routine audit and request the medical information necessary to verify the accuracy of the information reported on this form.

Prescriber Signature or Electronic I.D. Verification: ____

Date:

CONFIDENTIALITY NOTICE: The documents accompanying this transmission contain confidential health information that is legally privileged. If you are not the intended recipient, you are hereby notified that any disclosure, copying, distribution, or action taken in reliance on the contents of these documents is strictly prohibited. If you have received this information in error, please notify the sender immediately (via return FAX) and arrange for the return or destruction of these documents.

FAX THIS FORM TO: 800-424-7640

MAIL REQUESTS TO: Prime Therapeutics Management Prior Authorization Program

Attn: CP – 4201 P.O. Box 64811 St. Paul, MN 55164-0811

